ArticleEuropean journal of medical research2025
Free prostate-specific antigen, total prostate-specific antigen, and their ratio associated with diabetic kidney disease: new evidence from male patients with diabetes in the United States.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Repurposing a prostate tumor marker: elevated FPSA/TPSA ratio as a novel non-invasive biomarker for declining eGFR in male type 2 diabetes.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo examine the associations between prostate-specific antigen (PSA)-related biomarkers and diabetic kidney disease (DKD) in male patients with diabetes.
methodsThis study utilized data from the National Health and Nutrition Examination Survey (NHANES) conducted between 2001 and 2010, including 1,681 male diabetic patients (409 of whom had DKD). Multivariable logistic regression models adjusted for age, race, body mass index (BMI), hypertension, and cardiovascular disease were employed to evaluate the relationships between total PSA (TPSA), free PSA (FPSA), and the FPSA/TPSA ratio with DKD. Dose-response curves and subgroup analyses were performed to further assess these associations.
resultsElevated levels of TPSA, FPSA, and the FPSA/TPSA ratio were significantly associated with an increased risk of DKD. In fully adjusted models, the highest tertiles of TPSA (OR = 1.92, 95% CI 1.43-2.56) and FPSA (OR = 2.69, 95% CI 2.00-3.60) demonstrated the strongest associations. The FPSA/TPSA ratio exhibited a linear dose-response relationship with DKD (OR = 2.16, 95% CI 1.60-2.91), whereas TPSA and FPSA showed non-linear threshold effects. Subgroup analyses confirmed consistent findings across populations.
conclusionsPSA-related biomarkers may serve as potential indicators for early diagnosis and risk stratification of DKD. Further validation studies and mechanistic investigations are necessary to optimize clinical interventions and improve renal outcomes in diabetic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.